Related Experiment Video
Updated: Jul 12, 2026

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
Published on: September 22, 2014
Cell therapy in congestive heart failure
1Department of Cardiovascular Diseases, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China. taozw@hotmail.com
Insights
Congestive heart failure (CHF) research explores stem cell therapy. Bone marrow stem cells (BMCs) and cardiac stem cells (CSCs) show promise in animal models for heart repair, but clinical trial results are mixed.
Area of Science:
- Cardiology
- Regenerative Medicine
- Stem Cell Biology
Background:
- Congestive heart failure (CHF) is a growing global epidemic.
- Cardiomyocyte loss (necrosis and apoptosis) significantly contributes to CHF progression.
- Exogenous cell implantation presents a potential therapeutic strategy for CHF.
Purpose of the Study:
- To investigate the role of cardiac stem cells (CSCs) and bone marrow stem cells (BMCs) in heart repair.
- To evaluate the efficacy of stem cell therapy in treating congestive heart failure.
Main Methods:
- Studies involve observing CSC proliferation and BMC homing to injured cardiac tissue.
- Preclinical studies utilize stem cell transplantation in animal models of CHF.
- Clinical evaluation includes randomized, double-blind, placebo-controlled trials for BMC therapy.
Main Results:
- Basic studies in animals show improved ventricular remodeling and heart function with BMCs and CSCs.
- Clinical trials investigating BMC therapy for acute myocardial infarction have yielded inconsistent outcomes.
- Stem cells may reconstitute CSC populations and differentiate into cardiac tissue.
Conclusions:
- Stem cell therapy holds potential for treating CHF by promoting cardiac repair.
- Further research and clinical trials are needed to clarify the efficacy and optimal application of stem cell therapies in heart failure.
- The therapeutic benefits of BMCs in acute myocardial infarction require further investigation.
Abstract:
Congestive heart failure (CHF) has emerged as a major worldwide epidemic and its main causes seem to be the aging of the population and the survival of patients with post-myocardial infarction. Cardiomyocyte dropout (necrosis and apoptosis) plays a critical role in the progress of CHF; thus treatment of CHF by exogenous cell implantation will be a promising medical approach. In the acute phase of cardiac damage cardiac stem cells (CSCs) within the heart divide symmetrically and/or asymmetrically in response to the change of heart homeostasis, and at the same time homing of bone marrow stem cells (BMCs) to injured area is thought to occur, which not only reconstitutes CSC population to normal levels but also repairs the heart by differentiation into cardiac tissue. So far, basic studies by using potential sources such as BMCs and CSCs to treat animal CHF have shown improved ventricular remodelling and heart function. Recently, however, a few of randomized, double-blind, placebo-controlled clinical trials demonstrated mixed results in heart failure with BMC therapy during acute myocardial infarction.
Related Concept Videos
Heart Failure VI: Adjunct Therapies
Cardiomyopathy II: Dilated Cardiomyopathy
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Heart Failure II: Pathophysiology
Cardiomyopathy V: Interprofessional Care
Pathophysiology of Heart Failure

